| |
PVAN group |
Non-PVAN group |
P |
| Gender (Male/Female) |
20/11 |
208/112 |
>0.05 |
| Age (yr.) |
36.8±10.1 |
37.4±11.2 |
>0.05 |
| Postoperative onset time (mon) |
9.25±3.7 |
11.4±5.6 |
>0.05 |
| Historical events |
|
|
|
| Acute rejection (n/%) |
2 (6.5%) |
22 (6.9%) |
>0.05 |
| FK506 nephrotoxicity (n/%) |
4 (12.9%) |
16 ( 5.0%) |
<0.05 |
| Pneumonia (n/%) |
6 (19.4%) |
21 (6.6%) |
<0.05 |
| Immunosuppressive schema |
|
|
|
| CsA+MMF+Pred (CMP) |
6 (19.4%) |
60 (18.8%) |
>0.05 |
| Tac＋MMF+Pred (TMP） |
20(64.5%) |
188 (58.8%) |
>0.05 |
| Tac＋MMF+Pred+TII (TMPT) |
5(16.1%) |
72 (22.5%) |
>0.05 |
| Serum creatinine level (mg/dl) |
2.7±1.5 |
1.1±1.2 |
<0.05 |
| BKVAN: BK virus associated nephropathy
CsA: cyclosporine A, MMF: mycophenolate mofetil,Tac: tacrolimus,Pred: prednisone
TII: Tripterygium Wilfordii |
|
